|
|
100 Technology Drive, Suite 440B
Pittsburgh, PA 15219 USA
phone:412-621-9625
fax:
|
|
| Symbol |
Private |
| Founded |
1992 |
| Employees |
|
|
|
| www.demegen.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Peptides for the treatment or prevention of infections due to multi-drug resistant bacteria and fungi. |
|
| Management |
| Richard D. Ekstrom, Chairman of the Board, President, Chief Financial Officer, Secretary |
| |
|
|
| |
|
| Keywords |
| Cystic Fibrosis, Candidiasis, dermatology, small peptide |
|
|
|
| Description |
|
Demegen develops natural and novel peptides for the treatment or prevention of infections due to multi-drug resistant bacteria and fungi. Applications under development include dermatological, vaginal, respiratory, ophthalmic and oral diseases. |
|
| Products / Services |
Demegen's drugs destroy pathogens that are resistant to existing antibiotics and antifungals. Resistance is becoming a major health problem.
|
|
| Technology / Differentiation |
| Demegen's drugs are proprietary synthetic and natural peptides (small proteins). Antecedents for these compounds occur in nature as part of the immune system of animals, insects and plants. These new drugs are a new tool to combat bacterial and fungal infections, sexually transmitted diseases and cancer. Generally, the peptides bind to and kill harmful microorganisms and cancer cells. |
|
| Market / Customers |
Therapy for Lung Infections in Cystic Fibrosis; Oral Rinse for Candidiasis
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members